Latest News
Inhalon Biopharma to Present Inhaled Antibody Platform for Acute Respiratory Infections at ATS 2026 Respiratory Innovation Summit
Company selected to deliver oral presentation and poster showcasing clinical progress and preclinical data for first-in-class inhaled monoclonal antibody platform
Durham, North Carolina, May 11, 2026 — Inhalon Biopharma (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced that its chief executive officer, John Whelan, will provide an update on Inhalon’s progress at the Oral Showcase at the ATS 2026 Respiratory Innovation Summit (RIS), organized by the American Thoracic Society (ATS), taking place May 15 to 16, 2026 in Orlando, Florida.
Inhalon Biopharma is developing inhaled antibody therapeutics as potential treatments for a range of acute respiratory infections, such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and influenza.
The company’s platform delivers proprietary muco-trapping monoclonal antibodies directly to the airways via a handheld nebulizer, physically crosslinking respiratory viruses to secreted airway mucins and physically eliminating the viruses from the lung through the natural mucus clearance. In a Phase 1b clinical trial, inhaled dosing achieved vastly superior delivery to all parts of the respiratory tract compared to intravenous administration, validating Inhalon's core premise and vision to transform care for respiratory infections by enabling safe, effective, convenient, self-administered, outpatient treatments.
Mr. Whelan’s presentation is scheduled for Friday, May 15, 2026. An accompanying poster presentation will also be featured at the RIS.
About Inhalon Biopharma
Inhalon Biopharma, Inc. is a private, clinical-stage company advancing a first-in-class inhaled antibody platform for treating a range of acute respiratory infections. Inhalon Biopharma’s intellectual property includes U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Cambrian Growth Partners, Berkeley Catalyst Fund, JSR Life Sciences, and Life Science Angels, as well as numerous grants and contracts from the NIH and USAMRDC.
About the ATS 2026 Respiratory Innovation Summit
The ATS Respiratory Innovation Summit (RIS), held in conjunction with the American Thoracic Society International Conference (May 15–20, 2026) in Orlando, FL, is a premier forum for emerging companies presenting transformative respiratory science. The Oral Showcase is a competitively selective program highlighting companies offering differentiated approaches to unmet medical needs in respiratory disease.
Contact
John Whelan